Armistice Capital’s Kiora Pharmaceuticals KPRX Stock Holding History

Armistice Capital’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,296	Closed	-$12.2M	–	149
2021 Q2	$12.2M	Hold	9,296	–	–	0.22%	82
2021 Q1	$16.7M	Buy	9,296 +4,253	+84%	+$9.27M	0.38%	64
2020 Q4	$8.95M	Hold	5,043	–	–	0.3%	71
2020 Q3	$7.12M	Hold	5,043	–	–	0.26%	69
2020 Q2	$8.73M	Hold	5,043	–	–	0.38%	65
2020 Q1	$9.44M	Buy	5,043 +64	+1%	+$138K	0.58%	54
2019 Q4	$18M	Hold	4,979	–	–	1.04%	32
2019 Q3	$8.44M	Buy	4,979 +1,680	+51%	+$1.93M	0.56%	45
2019 Q2	$4.28M	Hold	3,299	–	–	0.27%	50
2019 Q1	$5.43M	Buy	3,299 +102	+3%	+$248K	0.3%	56
2018 Q4	$8.03M	Buy	3,197 +85	+3%	+$196K	0.61%	35
2018 Q3	$5.21M	Hold	3,112	–	–	0.31%	60
2018 Q2	$8.9M	Buy	3,112 +2,891	+1,308%	+$8.16M	0.58%	49
2018 Q1	$453K	Sell	221 -17	-7%	-$73.5K	0.03%	65
2017 Q4	$1.37M	Sell	238 -61	-20%	-$377K	0.14%	61
2017 Q3	$1.89M	Hold	299	–	–	0.22%	58
2017 Q2	$2.21M	Buy	+299	New	+$2.95M	0.28%	53

Other funds holding KPRX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SCA

Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tuttle Capital Management Riverside, Connecticut $60.8M AUM 17.47% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Armistice Capital's KPRX Position: Q3 2021 in Review

Armistice Capital sold out of Kiora Pharmaceuticals (KPRX) in Q3 2021, closing a stake of 9,296 shares — an estimated $12.2M sold.

Armistice Capital first reported a position in KPRX in Q2 2017 and held it in 17 quarters. The position peaked at $18M in Q4 2019. 19 funds tracked by Wall St. Rank hold KPRX as of Q3 2021.

Armistice Capital reported no remaining Kiora Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Armistice Capital sold 9,296 Kiora Pharmaceuticals shares in Q3 2021, an estimated $12.2M.
Armistice Capital first reported a position in Kiora Pharmaceuticals in Q2 2017 and held it in 17 quarters.
Armistice Capital's Kiora Pharmaceuticals position peaked at $18M in Q4 2019.
19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2021.

Based on Armistice Capital's 13F filing for Q3 2021, filed 15 Nov 2021.